dc.contributor
Institut Català de la Salut
dc.contributor
[Hannon G] Nanomedicine and Molecular Imaging Group, Department of Clinical Medicine, Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. Laboratory of Biological Characterization of Advanced Materials (LBCAM), Trinity Translational Medicine Institute, Trinity College Dublin, Dublin, Ireland. [Heaton BJ, Plant-Hately A, David C, Liptrott NJ] Immunocompatibility Group, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. Centre of Excellence for Long-Acting Therapeutics, Department of Pharmacology and Therapeutics, Institute of Systems, Molecular, and Integrative Biology, University of Liverpool, Liverpool, UK. [Egizabal A] TECNALIA, Basque Research and Technology Alliance (BRTA), Donostia-San Sebastián, Spain. [Abasolo I] Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain. Validació Funcional i Investigació Preclínica, Vall d’Hebron Institut de Recerca (VHIR), Universitat Autònoma de Barcelona, Bellaterra, Spain. [Andrade F] Grup de Bioquímica Clínica, Vehiculització de Fàrmacs i Teràpia, Vall d’Hebron Institut de Recerca (VHIR), Barcelona, Spain. Universitat Autònoma de Barcelona, Bellaterra, Spain. Networking Research Centre for Bioengineering, Biomaterials, and nanomedicine (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain
dc.contributor
Vall d'Hebron Barcelona Hospital Campus
dc.contributor.author
Hannon, Gary
dc.contributor.author
Heaton, Bethany Jane
dc.contributor.author
Plant-Hately, Alexander
dc.contributor.author
David, Christopher
dc.contributor.author
Liptrott, Neill
dc.contributor.author
Egizabal, Ainhoa
dc.contributor.author
Abasolo, Ibane
dc.contributor.author
Andrade, Fernanda
dc.date.accessioned
2025-10-24T08:57:17Z
dc.date.available
2025-10-24T08:57:17Z
dc.date.issued
2024-12-16T09:12:47Z
dc.date.issued
2024-12-16T09:12:47Z
dc.date.issued
2024-10-24
dc.identifier
Hannon G, Heaton BJ, Plant-Hately A, David C, Liptrott NJ, Egizabal A, et al. Interlaboratory comparison of endotoxin contamination assessment of nanomaterials. Nanoscale. 2024 Dec 7;16(45):21011–20.
dc.identifier
https://hdl.handle.net/11351/12334
dc.identifier
10.1039/d4nr02821j
dc.identifier
001339360500001
dc.identifier.uri
http://hdl.handle.net/11351/12334
dc.description.abstract
Assessment; Endotoxin; Nanomaterials
dc.description.abstract
Evaluación; Endotoxinas; Nanomateriales
dc.description.abstract
Avaluació; Endotoxines; Nanomaterials
dc.description.abstract
Endotoxin contamination is a significant hurdle to the translation of nanomaterials for biomedical applications. Multiple reports now describe that more than one-third of nanomaterials fail early pre-clinical assessment due to levels of endotoxin above regulatory requirements. Additionally, most immunological studies or in vivo studies testing nanomaterials in the literature lack inclusion of this assessment, which may lead to false-positive or false-negative results if high levels of the contaminant are present. The currently approved methods for endotoxin contamination assessment rely on enzymatic activity and wavelength absorbance as their endpoint, and many nanomaterials can interfere with such assays. For this reason, we devised an interlaboratory comparison of endotoxin contamination assessment for a range of nanomaterials to challenge the current international organization for standardization and pharmacopeia standards. Herein, we show that detected endotoxin levels could vary considerably between groups, and, in some instances, nanomaterials could both pass and fail regulatory endotoxin limits for medical devices depending on the group undertaking the assessment, all while passing all quality criteria standards. This work emphasises the requirement for multiple assays to fully assess the endotoxin levels in a nanomaterial and highlights the need for additional assays to be developed in this space.
dc.description.abstract
This work was funded by the European Commission's Horizon 2020 research and innovation programme (grant agreement: 814607).
dc.format
application/pdf
dc.publisher
Royal Society of Chemistry
dc.relation
Nanoscale;16(45)
dc.relation
https://doi.org/10.1039/d4nr02821j
dc.relation
info:eu-repo/grantAgreement/EC/H2020/814607
dc.rights
Attribution 4.0 International
dc.rights
http://creativecommons.org/licenses/by/4.0/
dc.rights
info:eu-repo/semantics/openAccess
dc.subject
Toxines bacterianes
dc.subject
Materials nanoestructurats
dc.subject
TECHNOLOGY, INDUSTRY, AND AGRICULTURE::Technology, Industry, and Agriculture::Manufactured Materials::Nanostructures
dc.subject
CHEMICALS AND DRUGS::Biological Factors::Toxins, Biological::Bacterial Toxins::Endotoxins
dc.subject
TECNOLOGÍA, INDUSTRIA Y AGRICULTURA::tecnología, industria y agricultura::productos manufacturados::nanoestructuras
dc.subject
COMPUESTOS QUÍMICOS Y DROGAS::factores biológicos::toxinas biológicas::toxinas bacterianas::endotoxinas
dc.title
Interlaboratory comparison of endotoxin contamination assessment of nanomaterials
dc.type
info:eu-repo/semantics/article
dc.type
info:eu-repo/semantics/publishedVersion